Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
41 hedge funds and large institutions have $12.2M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
45% more capital invested
Capital invested by funds: $8.41M → $12.2M (+$3.75M)
21% more funds holding
Funds holding: 34 → 41 (+7)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45.4K |
| 2 |
Renaissance Technologies
New York
|
+$45.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$34K |
| 5 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$74.1K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$9K |
| 3 |
D.E. Shaw & Co
New York
|
-$6.98K |
| 4 |
FA
FCG Advisors
Chatham,
New Jersey
|
-$6K |
| 5 |
DAM
Delta Asset Management
Memphis,
Tennessee
|
-$4.36K |
ONCT Hedge Fund Activity: Q3 2016 in Review
41 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2016, worth a combined $12.2M — up 45% from $8.41M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ONCT positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 10 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $45.4K. The largest seller was BlackRock Fund Advisors, cutting an estimated $74.1K.
- 41 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2016, up from 34 in Q2 2016.
- Funds reported $12.2M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2016, up 45% quarter-over-quarter.
- 9 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of +7 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2016 was Deutsche Bank, an estimated $45.4K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2016 was BlackRock Fund Advisors, an estimated $74.1K sold.
Based on aggregated 13F filings for Q3 2016.